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Abbreviations 
AIMP- Aminoacyl tRNA synthetase-interacting multifunctional protein 
ARS- Aminoacyl-tRNA Synthetases 
ATCC- American Type Culture Collection 
BSA- Bovine Serum Albumin 
FBS- Fetal Bovine Serum 
LARS- Leucyl-tRNA Synthetase 
MSC- Multi-tRNA Synthetase Complex 
PBS- Phosphate-Buffered Saline 
PCR- Polymerase Chain Reaction  
SDS- Sodium Dodecyl Sulfate 
TBST- Tris Buffered Saline with Tween-20 
Tris-HCl- Tris (hydroxymethyl) aminomethane hydrochloride 
VARS- Valyl-tRNA Synthetase 
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Abstract 
In mammalian cells, a multi-tRNA synthetase complex containing eight aminoacyl-tRNA 
synthetases, which catalyze nine different reactions, is thought to make protein synthesis more 
efficient by keeping components of the translational machinery in close proximity. Aminoacyl 
tRNA synthetase-interacting multifunctional protein 2 (AIMP2) is one of three non-catalytic 
components of this complex and is essential for its formation and stability. A homozygous 
nonsense variant (Y35Ter) of AIMP2 appears in the genotypes of patients with severe 
neurodevelopmental phenotypes. To determine the effect this variant has on expression at the 
mRNA and protein level, as well as progression of cells through the cell cycle, patient fibroblasts 
were studied. Fluorescent microscopy and western blotting, along with puromycin-labeling, cell 
synchronization, and mRNA analysis, were used to determine the cellular impact of this 
mutation. Through this study, it was determined that this mutation in AIMP2 causes decreased 
AIMP2 protein levels and altered mRNA expression. Along with that, the puromycin assay 
showed a lower rate of protein synthesis in patient fibroblasts when compared to ATCC control 
cells. There was also a slight decrease in the amount of leucyl-tRNA synthetase (LARS) in 
patient cells. This protein is a member of the multi-tRNA synthetase complex and the observed 
decrease could indicate that the protein level of other members of the complex are lower in 
patient cells. While the cell cycle study did not provide any significant results, this could be due 
to the fact that fibroblasts were used and not neuronal cells. This study showed that 
a homozygous nonsense variant (Y35Ter) of AIMP2 impacts expression at the mRNA and 
protein level while also decreasing protein synthesis. Further research into the specific 
mechanism behind this mutation is needed in order to possibly develop a treatment option for 
patients presenting with the resulting symptoms. 
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Introduction 
 Within the central dogma of cellular biology, there are many crucial molecules that allow 
for the replication, transcription, and translation of DNA and genes within the body. One family 
of molecules that are essential for the translation of messenger RNA to proteins are aminoacyl-
tRNA synthetases (ARSs). These enzymes ligate amino acids to the correct tRNA allowing for 
the proper assembly of proteins1. The specificity of these enzymes for a particular amino acid is 
critical to maintaining the fidelity of the genetic code, and thus maintenance of cellular 
homeostasis. Within mammalian cells, eight different ARS, which catalyze nine different 
reactions, are found in the multi-tRNA synthetase complex (MSC)2. It is believed that this 
complex keeps ARS and other translational components in close proximity, in turn making 
protein synthesis more efficient. For this complex to assemble, three proteins called aminoacyl 
tRNA synthetase-interacting multifunctional proteins (AIMP 1-3), are involved with protein-
protein interactions and is mediated by heat-shock protein 901.  
 AIMP2, also known as p38, is one of the non-catalytic components of the MSC and is 
essential for its formation and stability. The function of AMIP2 is indispensable, as evidenced by 
embryonic lethality observed in AMP2 knockout mice. In fibroblasts cultured from these mice 
prior to death, western blot analysis demonstrated that the protein levels of AIMP1, AIMP2, and 
various ARS that are contained within the MSC was dramatically decreased1. AIMP2 knockout 
did not alter messenger RNA levels of the AIMPs or ARS that showed decreased protein levels, 
indicating that decreased levels of MSC components did not result from altered transcription1.  
Mutations in various components of the MSC have been shown to cause various 
neurodevelopmental disorders2-4. For example, the glutamyl-prolyl-tRNA synthetase (EPRS) is 
one member of the MSC that, when mutated, causes a loss of protein function, resulting in a 
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severe neurodevelopmental phenotype that presents with microcephaly, epilepsy and cognitive 
impairment4. Other ARS mutations also cause neurodevelopmental disorders, including valyl-
tRNA synthetase (VARS) mutations. When the effect of VARS knockout was explored in 
mutant zebrafish, the resulting phenotype included epileptic activity which was also seen in 
patients with the mutation5. While determining a causal relationship between the mutant 
genotype and the resulting phenotype is important, it is also important to determine if there is a 
way to fix the neurological symptoms. In the case of the VARS mutation in zebrafish, rescuing 
the gene by injecting wildtype mRNA seemed to result in a normal phenotype for the early 
stages of growth5. While the zebrafish model isn’t a perfect representation of this disease, these 
results indicate that there may be a way to mitigate the detrimental neurological effects these 
types of mutations have. 
A nonsense variant of AIMP2 is associated with severe neurodevelopmental phenotypes 
similar to those that result from various ARS mutations3. This phenotype is characterized by 
microcephaly, seizures, spastic quadriparesis, and cognitive impairment3. This association was 
determined using whole-exome sequencing in patients who have the symptoms. The genotypes 
identified from the sequencing determined three mutations that cause the phenotype: a 
homozygous nonsense variant, a homozygous splice-site mutation, and compound heterozygous 
nonsense and splice-site mutations3. The similarity of the mutant AIMP2 phenotype with the 
phenotype of other mutant ARS, may indicate that the mutations cause disease through a similar 
molecular pathway. In this work, the effect a of homozygous nonsense variant (Y35Ter) on 
expression at the mRNA and protein level, as well as progression of cells through the cell cycle 
will be investigated to learn more about how the neurodevelopmental phenotype arises.  
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Materials and Methods 
Cell Culture 
 Fibroblasts from patients were collected by collaborators and control cells were obtained 
from the American Type Culture Collection (ATCC). All cells were maintained in an incubator 
kept at 37 °C and 5% CO2 and grown in high glucose Dulbecco’s Modified Eagle Medium media 
supplemented with 5% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin-
streptomycin.  When the cells were between 75% and 90% confluent, they were split by 
removing the media and washing with Dulbecco’s phosphate-buffered saline. Then, 0.25% 
trypsin was added to the cells, incubated for 30 seconds, and then removed. The plate and flask 
were placed in the incubator for two minutes and then the cells were re-suspended in the media 
they were originally grown in. An appropriate dilution was made and placed in new plates or 
flasks. 
Fluorescent Microscopy 
 Cells were plated into a 24-well plate with small coverslips in each well. The cells were 
washed in phosphate-buffered saline (PBS) and then fixed to the coverslips with 4% 
paraformaldehyde in 1x PBS for 20 minutes. After washing the fixation solution off with PBS, 
the cells underwent permeabilization and blocking for an hour in PBS with 5% BSA and 0.1% 
triton-X100. The primary antibody for AIMP2 was applied at a concentration of 0.001 μg/mL in 
PBS with 3% bovine serum albumin (BSA) and 0.1% triton-X100 and incubated at 4ºC 
overnight in a humidity chamber. After the primary incubation, the cells were washed with PBS 
before the secondary was added at a concentration of 1:500. The cells were incubated in the 
secondary for an hour and a half in the dark at room temperature before being washed with PBS 
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followed by water. The coverslips were mounted to slides using ProlongGold and imaged on an 
epifluorescence microscope.  
Sodium Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 The various plates of cells were lysed using an M-cell lytic solution with protease and 
phosphate inhibitors. The resulting solution was pelleted to remove unnecessary cellular debris. 
To determine the protein concentration of the various cell solutions, a Bradford assay was 
performed using standards of 2000 μg/mL, 1500 μg/mL, 1000 μg/mL, 750 μg/mL, 500 μg/mL, 
250 μg/mL, and 125 μg/mL of BSA6. Depending on the concentration of protein in the cell 
lysates, either 15 μg or 10 μg were used to run on the gel; however, each gel was run with a 
consistent amount of protein. Before loading the gel, 4x SDS loading dye containing 50 mM Tris 
(hydroxymethyl) aminomethane hydrochloride (Tris-HCl) pH 6.8, 2% sodium dodecyl sulfate 
(SDS), 10% glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA and 0.02% bromophenol blue was 
added to the samples and they were boiled for ten minutes at 100ºC. The samples were loaded 
onto a 10% polyacrylamide gel with a 5% stacking gel and run in a buffer containing 25 mM 
Tris, 192 mM glycine, and 0.1% SDS. The gel was run at 100 V for about ten minutes until the 
samples were through the stacking gel and then the gel was run at 200 V for about 45 minutes.  
Western Blotting 
 Fiber pads, filter papers, and the nitrocellulose membrane were soaked in the cold 
transfer buffer for ten minutes before being placed in the cassette with the gel. The assembly of 
the gel and membrane in the cassette was performed win a container with cold transfer buffer to 
ensure there were no air bubbles and that each piece was soaked. Once the cassette was placed 
into the running container, an ice block was placed in the container along with a stir bar to 
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prevent localized areas of heat. Ice was then packed around the container to keep the buffer cold. 
The transfer was run at 80 V for one hour. To ensure the transfer was successful, the membrane 
was briefly stained with ponceau stain. This ensures the lanes ran straight and that no bubbles 
occurred throughout the transfer.  
 The completed transfer membrane was blocked with 5% BSA in TBST overnight in a 
cold room. The block was removed and the membrane was washed with TBST for about an hour. 
A primary, anti-AIMP2 antibody in 3% BSA with Tris buffered saline with Tween-20 (TBST) 
containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, and 0.1% Tween-20 was placed on the 
membrane and incubated for about an hour. Following incubation, the membrane was again 
washed for an hour with TBST and then incubated in an HRP goat secondary antibody for an 
hour. This was followed by a wash as described above. Proteins on the blot were visualized by 
briefly incubating with Clarity ECL Western Substrate. Protein levels were quantified by 
performing densitometry in ImageJ. 
Puromycin Assay 
 Cells were plated onto small coverslips as described in the fluorescence microscopy 
methods. The cells were then treated with puromycin for 30 minutes before being fixed to the 
coverslips with paraformaldehyde. A ‘click-chemistry’ reaction was then performed to attach 
Alexa 594, a fluorescent probe, to the puromycin7. The relative intensity of fluorescence was 
measured using a fluorescent microscope to determine how much puromycin was incorporated 
into nascent polypeptides in order to determine the rate of protein synthesis. 
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Messenger RNA Analysis 
 Cells were cultured in the appropriate media as described above. Some flasks and plates, 
containing patient fibroblasts or ATCC cells respectively, were treated with cycloheximide while 
others were kept as controls. RNA was isolated from cells using the QIAGEN RNeasy® Mini 
column. Once the RNA was isolated, the samples were put through reverse transcription in order 
to create a cDNA library of the genes. A high-capacity cDNA reverse transcription kit from 
ThermoFisher Scientific was used and the reaction was run with an RNase inhibitor. A 
polymerase chain reaction (PCR) was utilized to amplify the cDNA corresponding to the mRNA 
of AIMP2. This was performed using Q5® High-fidelity DNA Polymerase. The reaction was run 
with 1x Q5 Reaction Buffer, 200 μM dNTPs, 0.5 μM of both the JTV11 and JTV13 primers, 1 
μL of sample DNA, 0.02 U/μL of Q5 High Fidelity DNA Polymerase, 1X Q5 High GC 
Enhancer, and nuclease-free water. Samples from the patient fibroblasts and the ATCC cells both 
with and without the presence of cycloheximide were used as samples for this process 
Cell Cycle Analysis 
 Patient and ATCC cells were re-suspended in a minimal amount of media. Each type of 
cell was mixed one to one with trypan blue dye and then placed into a cell counting chamber 
slide. A CountessTM (Invitrogen) machine was used to calculate the number of cells contained in 
a milliliter of the re-suspension along with determining the percent viability. Both ATCC and 
patient cells were plated onto a six well plate with 2.66x105 cells for the entire plate. The cells 
were allowed to grow for a few days until they were adherent. Media was then removed and 
reduced serum media was added to synchronize cells. This was left on for approximately 40 
hours. Media was then returned to the cells at intervals so that when they were lysed, the cells 
had been in full media for 10, 9, 8, 7, 6 hours, and 30 minutes. The cells were once again lysed in 
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M-cell lytic. The resulting lysates underwent an SDS-PAGE and a western blot as described 
above; however, the antibody used was for cyclin D1. 
Results and Discussion 
AIMP2 mRNA and Protein Levels 
 While previous studies into the MSC and the AIMP molecules that help the complex 
come together have shown that some mutations that occur within the complex cause 
neurodevelopmental disorders, research into mutations in the AIMP2 gene is sparse. It was 
determined through genome sequencing that patients exhibiting a neurodevelopmental phenotype 
had homozygous nonsense mutations, Y35Ter, in the gene coding for AIMP23. Through the 
collection and analysis of the mRNA, it is clear that mRNA expression is altered in patient cells 
(Figure 1A). While the full length AIMP2 mRNA level seems to remain consistent, the splice 
variant which does not contain exon two, along with an unknown form are dramatically 
decreased in patient cells (Figure 1A). To further understand what was occurring with the 
mRNA, the cells were treated with cycloheximide, which is known to inhibit the degradation of 
mRNA8. Treatment with cycloheximide appeared to normalize the mRNA expression pattern in 
patient cells, suggesting that nonsense-mediated decay may be occurring (Figure 1A). 
 After identifying differences at the mRNA level, the next step was to analyze the level of 
AIMP2 protein within the cells. Through western blot analysis, we determined that AIMP2 
protein levels were dramatically decreased in patient cells compared to ATCC control fibroblasts 
(Figure 1B). The protein levels were normalized to a loading control and t-test analysis (p<.05) 
confirmed a significant reduction of AIMP2 in patient fibroblasts (Figure 1B). Fluorescence 
microscopy was also used to study the level and localization of AIMP2 within the cell. The 
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fluorescence imaging confirms that AIMP2 levels are reduced in patient cells and shows that 
wild-type AIMP2 is localized diffusely throughout the cytoplasm with a slight enrichment 
around the nucleus (Figure 1C). 
Protein Synthesis 
 Once it was determined that both the mRNA expression and the protein level of AIMP2 
were altered, it was important to study how this affected overall protein synthesis. AIMP2 is 
known to be an integral part of the formation of the MSC which is heavily involved in 
mammalian protein synthesis1. To study protein synthesis, cells were treated with puromycin. 
The puromycin is incorporated into nascent polypeptides9. This, along with a fluorescent probe 
that binds to the puromycin, allows protein synthesis rate to be analyzed9. When this was 
performed on patient fibroblasts and ATCC cells, there was a lower rate of protein synthesis in 
patient cells (Figure 2). This decrease cannot be considered statistically significant until this 
experiment is replicated and concludes consistent results. If the results of the replications are 
consistent, it would support the idea that this mutation significantly impacts protein synthesis. 
This leads to the idea that even this slight decrease in the rate of protein synthesis could 
dramatically impact how the rest of the cell functions. 
Levels of the MSC associated leucyl-tRNA synthetase 
 While the nonsense mutation in AIMP2 seems to cause a decrease in the rate of protein 
synthesis, it does not actively have a catalytic function. The enzymes that are associated with 
AIMP2 are the ARS which charge tRNAs with the correct amino acid2. Due to the role AIMP2 
plays within the MSC, when it is mutated, the MSC either falls apart or cannot form in the first 
place1. To further understand how the MSC and its individual parts are impacted by the AIMP2 
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mutation, another component was analyzed through western blotting. Leucyl-tRNA synthetase 
(LARS) is a component of the MSC that appears to closely associated to AIMP21. When the 
protein level of LARS was analyzed in patient fibroblast, there appeared to be a slight decrease 
when compared to ATCC cells (Figure 3). This is an important result because it could mean that 
the inability to form the MSC leads to ARS degradation in patient fibroblast. Further research is 
needed to determine if this is an isolated incident or if it happens among all of the ARS that are 
located within the MSC.  
Cell Cycle 
 One important idea as to how the mutation in AIMP2 causes the neurodevelopmental 
phenotype relates to defects in cell cycle progression. It was hypothesized that the mutation 
altered the cell’s ability to progress through the cell cycle which could in turn cause 
microcephaly. To study the progression from G1 to S phase in the cell cycle, cyclin D1 levels 
were analyzed in an unsynchronized cell population along with cells that were synchronized 
through serum starvation. Cyclin D1 is one of the first cyclin molecules to be upregulated in the 
cell cycle and this molecule determines the cell’s progression into the proliferation process10. 
When the levels of cyclin D1 in patient fibroblasts and ATCC cells was measured, there seemed 
to be very little difference between the two groups. For the unsynchronized study, there was a 
trend towards decreased cyclin D1 levels in patient cells, but no statistically significant 
difference between the patient fibroblasts and ATCC cells (Figure 4B). When the cell cycles 
were synchronized, the resulting expression of cyclin D1 was inconclusive. The protein levels 
clearly increased after serum administration at the different time points, but there was no 
significant difference between the patient fibroblasts and ATCC cells in either of the trials 
(Figure 4A). 
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 These results do not support the hypothesis that the cell cycle is being impacted by this 
mutation; however, it does not exactly refute it either. The cells that were studied in this 
experiment were skin fibroblasts. These are fairly easily obtained from patients and can be easily 
cultured once the correct conditions are determined. For some experiments, such as analyzing 
protein levels and protein synthesis, patient fibroblasts can be extremely useful. The downfall, in 
this case however, is that the mutation in AIMP2 causes neurodevelopmental phenotypes which 
means that this mutation is specifically causing something to occur in neurons. Neurons are 
different from fibroblasts in many ways, so it is hard to fully understand what is occurring in the 
neurons by studying fibroblasts. So, while the fibroblasts are not showing that a mutation in 
AIMP2 impacts the cell cycle, it is very possible that neuronal cell proliferation is affected in 
some way. 
Future Studies and Significance 
 While studying patient permits the determination of how the AIMP2 mutation impacts 
protein expression and synthesis, it is important to further study how the mutation affects 
neurons. Obtaining patient neurons is not an option so creating a mutant line of neurons is 
necessary. This was attempted in PC12 cells which are rat pheochromocytoma cells11. The 
transfection of previously studied ARS mutations was attempted with no success. Further studies 
into the AIMP2 mutation would require the development or identification of a neuronal cell line 
that can be easily transfected for study.  
 This nonsense mutation in AIMP2 causes a severe neurodevelopmental phenotype in the 
patients who have it. While the specific mechanism as to how the mutation causes microcephaly 
and the other neurological symptoms is unknown, these results start to pave the way for 
determining the pathophysiology of this disorder. These results support the hypothesis that the 
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mutation causes decreased AIMP2 protein levels which impacts the function of the MSC and its 
associated ARS. These changes lead to the neurodevelopmental phenotype seen in patients. 
Hopefully, by understanding the change in protein level and the rate of synthesis, future studies 
can build upon this research and work towards a cure or treatment. Without knowing how the 
mutation causes the phenotype, treating or curing the resulting disorder is nearly impossible. 
There is still a lot of work to be done before a treatment can even be thought about, but with 
current technological advances in all areas of research, along with these initial results, further 
studies can be done to understand the mutation and possibly alleviate the symptoms.  
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Figures 
 
Figure 1. Analysis of AIMP2 protein levels in patient fibroblasts and ATCC cells. A. RT-PCR 
of AIMP2 mRNA along with a β-Actin loading control. The same was performed on cells treated 
with cycloheximide. B. Western blot analysis comparing the amount of AIMP2 in ATCC cells 
and patient fibroblasts. β-Actin was used as a loading control in order to normalize the data. The 
resulting graph shows the comparison between the normalized intensity of AIMP2 along with the 
statistical significance of the difference between the two experimental conditions (*). C. ATCC 
cells and patient fibroblasts were tagged with an antibody for AIMP2 (0.001 μg/mL) and then 
imaged using fluorescence microscopy. The relative intensity of the fluorescence of the cells was 
measured across numerous cells and averaged to determine statistical significance (*). 
 
 
 
 
 
control           Y35Ter 
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Figure 2. Puromycin treated cells with a ‘click-chemistry’ fluorescent probe, Alexa 594, 
attached to the puromycin. The relative intensity of the fluorescence of numerous cells was 
measured and normalized. Puromycin is incorporated into forming polypeptides so the 
fluorescence shows relative protein synthesis. 
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Figure 3. Western blot analysis comparing the amount of AIMP2 and LARS in ATCC cells and 
patient fibroblasts. Vinculin was used as a loading control in order to normalize the data. Clarity 
ECL Western Substrate was used to visualize these proteins.  
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Figure 4. Cell cycle analysis of western blots with an antibody to Cyclin D1 to determine how 
AIMP2 impacts cell cycle progression. A. The cell growth and starvation were synchronized in 
order to determine the cells ability to make Cyclin D1 at certain points in the cell cycle. The 
relative intensity of the Cyclin D1 was normalized to either vinculin or β-Actin depending on 
how well the antibody worked. The data were then normalized to the zero time point. B. Western 
blot analysis comparing the amount of Cyclin D1 in ATCC cells and patient fibroblasts that had 
unsynchronized cell cycles. The resulting graph shows the comparison between the Cyclin D1 
levels of the two groups when compared to vinculin as a loading control. 
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